Online inquiry

IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5060MR)

This product GTTS-WQ5060MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Hidradenitis suppurativa (HS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5060MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4416MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ14826MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ10877MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ6588MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ6136MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ13080MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ11112MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ6207MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW